News

The appellate court issued an order prohibiting regulatory approval of Ranbaxy’s product in Canada until Pfizer’s enantiomer (calcium salt) patent expires in July 2010. Ranbaxy may seek a

The Court also denied Perrigo’s motion for summary judgment based on non- infringement. The case will now proceed to trial with the trial date not having been set.

This decision comes following an appeal the company filed after a previous negative opinion was adopted by the CHMP in November 2007 and only applies to UCB’s filing

In reaching this opinion, the European Committee for Medicinal Products for Human Use (CHMP) stated that further data are required to support the results from EpiCept’s Phase III

Results from a Phase I study in onychomycosis, as well as preclinical data, indicated that the product can be safely applied to the skin at doses more than

Artiss was developed using Baxter’s proven fibrin sealant technology platform and is the newest agent in the company’s expanding BioSurgery portfolio. It is a biologically active sealant consisting

This includes a second generation recombinant Protective Antigen (rPA) anthrax vaccine, a recombinant dual antigen plague vaccine, and a third generation rPA anthrax vaccine program. As part of

The Treanda application as a chronic lymphocytic leukemia (CLL) treatment received priority review from the FDA and was approved within six months of the September 2007 submission. Cephalon

The open-label Phase Ib study will assess escalating doses of NPI-2358 in combination with docetaxel in patients with non-small cell lung cancer (NSCLC) who previously failed at least